Pharmaceutical company Breckenridge Pharmaceutical Inc disclosed on Wednesday the receipt of the US Food and Drug Administration's final approval for its Abbreviated New Drug Application for Exemestane Tablets in 25mg.
The company added that the Exemestane Tablets in 25mg is the generic version of Pfizer's Aromasin Tablets.
In conjunction, Breckenridge's Exemestane Tablets product was developed in collaboration with Medikl Ltd and MSN Laboratories Private Ltd. MSN will manufacture and supply the product from its facilities in Hyderabad, India. Additional announcements will be made prior to product launch.
For the 12 months ending 31 December 2018, Exemestane Tablets generated annual sales of USD65m, according to industry sales data.
Exemestane Tablets is reportedly used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US